GPNMB, glycoprotein nmb, 10457

N. diseases: 103; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.080 Biomarker group BEFREE Importantly, knockdown of GPNMB blunted the influence of CAF on enhanced cancer invasion. 30992322 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.080 Biomarker group BEFREE Although it is known that EMT is associated with not only cancer invasion but also acquisition of cancer stem cell (CSC) properties, the function of GPNMB in this acquisition of CSC properties has yet to be elucidated. 30224376 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.080 Biomarker group BEFREE Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. 28546082 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.080 Biomarker group BEFREE Glycoprotein nonmetastatic melanoma protein B is a type 1 transmembrane protein that has been recently found to play a role in cancer cell proliferation, angiogenesis, and invasion. 28443476 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.080 Biomarker group BEFREE ASPS tumor cells also demonstrated enhanced transendothelial migration activity, which was inhibited by silencing of <i>Gpnmb</i>, indicating that GPNMB plays an important role in tumor intravasation, a key step in cancer metastasis. 27979841 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.080 Biomarker group BEFREE The combination of MAPK pathway inhibitors with an antibody-drug conjugate targeting GPNMB is an effective therapeutic option for patients with melanoma.Clin Cancer Res; 22(24); 6088-98.©2016 AACR. 27515299 2016
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.080 Biomarker group BEFREE Glycoprotein nonmetastatic melanoma protein B (GPNMB), initially termed glycoprotein nonmetastatic gene B and also named osteoactivin (OA), is a type 1 transmembrane protein that has been recently found to play a role in cancer cell proliferation, angiogenesis, and invasion. 25426614 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.080 Biomarker group BEFREE In addition, we touch on the therapeutic potential of osteoactivin in cancer and bone diseases. 21395506 2010